778-P: Efficacy and Safety of Supaglutide as Add-on to Metformin in Patients with Type 2 Diabetes
Author:
ANWAR DILBAR1, BAO YUQIAN1, ZHOU YUE1, CHEN SI1, ZHOU JIAN1, LI LIANG1, CHENG ZHIFENG1, DONG XIAOLIN1, SHI XIAOXIA1, SU XIUHAI1, LI LIPING1, WANG HAIFANG1, WANG YIHUA1, LI SHU1, LI QINGJU1, LI XING1, LIU MING1, SUN JIAO1, ZHAO NAIQING1, YANG YEHONG1, MA JIANHUA1, LI YIMING1, WANG QINGHUA1, JIA WEIPING1
Affiliation:
1. Haerbin, China, Jinan, China, Cangzhou, China, Luoyang, China, Handan, China, Nanyang, China, Huizhou, China, Henan, China, Taiyuan, China, Tianjin, China, Shanghai, China, Nanjing, China
Abstract
GLP-1 is an incretin hormone with broad pharmacological potential. GLP-1 receptor agonists (GLP-1RA) are successfully in clinical use for T2D and obesity. Several GLP-1-based therapies are in clinical evaluation for treating metabolic diseases. Supaglutide (supa), a novel GLP-1RA, is in late-stage clinical investigation for T2D. The efficacy and safety are being investigated in 340 patients with T2D inadequately controlled on metformin in this randomized, double-blind, placebo-controlled phase 3 clinical trial (NCT04998032). Supa 3 mg QW treatment resulted in a statistically significant reduction in HbA1c of -1.81% from baseline at week 24 (p<0.001). Body weight was decreased by 3.80% from baseline in supa 3 mg group, with a significant difference versus placebo group (p<0.001). Supa also significantly improved glucose excursion, and increased meal-stimulated insulin and C-peptide secretion as determined by MMTT, suggesting improved glucose tolerance and enhanced β-cell function. Overall TEAEs occurred in 66.7% and 73.4% with placebo and supa 3 mg, respectively. The most common TEAEs with supa were GI symptoms, such as nausea, vomiting, diarrhea and decreased appetite mostly in mild or moderate severity. Supa 3 mg improved glycemic and metabolic control and was well tolerated in T2D inadequately controlled on metformin, suggesting supa as a novel alternative therapy for T2D and metabolic disorders.
Disclosure
D.Anwar: None. X.Su: None. L.Li: None. H.Wang: None. Y.Wang: None. S.Li: None. Q.Li: None. X.Li: None. M.Liu: None. J.Sun: None. N.Zhao: None. Y.Bao: None. Y.Yang: None. J.Ma: None. Y.Li: None. Q.Wang: None. W.Jia: None. Y.Zhou: None. S.Chen: None. J.Zhou: None. L.Li: None. Z.Cheng: None. X.Dong: None. X.Shi: None.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
|
|